{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:13:53Z","timestamp":1791918833177,"version":"4.3.4"},"reference-count":136,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MRC","award":["MR\/N013867\/1"],"award-info":[{"award-number":["MR\/N013867\/1"]}]},{"name":"MRC","award":["ARUK-PPG2021B-012"],"award-info":[{"award-number":["ARUK-PPG2021B-012"]}]},{"name":"Alzheimer\u2019s Research UK (ARUK) Pilot","award":["MR\/N013867\/1"],"award-info":[{"award-number":["MR\/N013867\/1"]}]},{"name":"Alzheimer\u2019s Research UK (ARUK) Pilot","award":["ARUK-PPG2021B-012"],"award-info":[{"award-number":["ARUK-PPG2021B-012"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Dementia exists as a \u2018progressive clinical syndrome of deteriorating mental function significant enough to interfere with activities of daily living\u2019, with the most prevalent type of dementia being Alzheimer\u2019s disease (AD), accounting for about 80% of diagnosed cases. AD is associated with an increased risk of comorbidity with other clinical conditions such as hypertension, diabetes, and neuropsychiatric symptoms (NPS) including, agitation, anxiety, and depression as well as increased mortality in late life. For example, up to 70% of patients diagnosed with AD are affected by anxiety. As aging is the major risk factor for AD, this represents a huge global burden in ageing populations. Over the last 10 years, significant efforts have been made to recognize the complexity of AD and understand the aetiology and pathophysiology of the disease as well as biomarkers for early detection. Yet, earlier treatment options, including acetylcholinesterase inhibitors and glutamate receptor regulators, have been limited as they work by targeting the symptoms, with only the more recent FDA-approved drugs being designed to target amyloid-\u03b2 protein with the aim of slowing down the progression of the disease. However, these drugs may only help temporarily, cannot stop or reverse the disease, and do not act by reducing NPS associated with AD. The first-line treatment options for the management of NPS are selective serotonin reuptake inhibitors\/selective noradrenaline reuptake inhibitors (SSRIs\/SNRIs) targeting the monoaminergic system; however, they are not rational drug choices for the management of anxiety disorders since the GABAergic system has a prominent role in their development. Considering the overall treatment failures and side effects of currently available medication, there is an unmet clinical need for rationally designed therapies for anxiety disorders associated with AD. In this review, we summarize the current status of the therapy of AD and aim to highlight novel angles for future drug therapy in our ongoing efforts to alleviate the cognitive deficits and NPS associated with this devastating disease.<\/jats:p>","DOI":"10.3390\/ijms25105169","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T03:21:04Z","timestamp":1715311264000},"page":"5169","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"25","author":[{"given":"Jialin","family":"Li","sequence":"first","affiliation":[{"name":"UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Haj Ebrahimi","sequence":"additional","affiliation":[{"name":"UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-5609","authenticated-orcid":false,"given":"Afia B.","family":"Ali","sequence":"additional","affiliation":[{"name":"UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Silva, M.V.F., Loures, C.d.M.G., Alves, L.C.V., de Souza, L.C., Borges, K.B.G., and Carvalho, M.d.G. (2019). Alzheimer\u2019s disease: Risk factors and potentially protective measures. J. Biomed. Sci., 26.","DOI":"10.1186\/s12929-019-0524-y"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1515\/jbcpp-2023-0264","article-title":"Alzheimer\u2019s disease and clinical trials","volume":"35","author":"Paul","year":"2024","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3233\/JAD-231163","article-title":"Alzheimer\u2019s Disease Immunotherapy: Current Strategies and Future Prospects","volume":"98","author":"Aljassabi","year":"2024","journal-title":"J. Alzheimers Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer\u2019s disease and the amyloid-beta peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ana.410220110","article-title":"Alzheimer\u2019s disease: Glutamate depletion in the hippocampal perforant pathway zone","volume":"22","author":"Hyman","year":"1987","journal-title":"Ann. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4236\/ym.2018.24025","article-title":"The Beneficial Effect of Enriched Environment on Pathogenesis of Alzheimer\u2019s Disease","volume":"2","author":"Chen","year":"2018","journal-title":"Yangtze Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-12-804766-8.00013-3","article-title":"Chapter 13\u2014Alzheimer\u2019s disease","volume":"Volume 167","author":"Dekosky","year":"2019","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Breijyeh, Z., and Karaman, R. (2020). Comprehensive Review on Alzheimer\u2019s Disease: Causes and Treatment. Molecules, 25.","DOI":"10.3390\/molecules25245789"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lanoisel\u00e9e, H.M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., and Martinaud, O. (2017). APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med., 14.","DOI":"10.1371\/journal.pmed.1002270"},{"key":"ref_10","first-page":"313","article-title":"The Epidemiology of Alzheimer\u2019s Disease Modifiable Risk Factors and Prevention","volume":"8","author":"Zhang","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/j.2051-5545.2010.tb00298.x","article-title":"Pathophysiology of depression: Do we have any solid evidence of interest to clinicians?","volume":"9","author":"Hasler","year":"2010","journal-title":"World Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0165-0327(02)00426-3","article-title":"Epidemiology of women and depression","volume":"74","author":"Kessler","year":"2003","journal-title":"J. Affect. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/bjc.12360","article-title":"Investigating the prevalence of anxiety and depression during the first COVID-19 lockdown in the United Kingdom: Systematic review and meta-analyses","volume":"61","author":"Dettmann","year":"2022","journal-title":"Br. J. Clin. Psychol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(21)00359-7","article-title":"Anxiety disorders","volume":"397","author":"Penninx","year":"2021","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/ADR-210294","article-title":"The Relationship Between Anxiety and Alzheimer\u2019s Disease","volume":"5","author":"Mendez","year":"2021","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1007\/s10072-022-06068-x","article-title":"Anxiety and depression in Alzheimer\u2019s disease: A systematic review of pathogenetic mechanisms and relation to cognitive decline","volume":"43","author":"Botto","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer\u2019s disease: Recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1161\/01.CIR.0000086899.32832.EC","article-title":"Computed Tomography Scan and Magnetic Resonance Imaging","volume":"108","author":"Kwong","year":"2003","journal-title":"Circulation"},{"key":"ref_19","unstructured":"Zeisel, J., Bennett, K., and Fleming, R. (2020). World Alzheimer Report 2020: Design, Dignity, Dementia: Dementia-Related Design and the Built Environment, Alzheimer\u2019s Disease International."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jalz.2009.03.001","article-title":"2009 Alzheimer\u2019s disease facts and figures","volume":"5","year":"2009","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/WAD.0b013e3182163b62","article-title":"Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment and Alzheimer\u2019s disease","volume":"26","author":"Apostolova","year":"2012","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","article-title":"Alzheimer\u2019s disease: Experimental models and reality","volume":"133","author":"Drummond","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u2019s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40263-019-00672-w","article-title":"Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression","volume":"33","author":"Cooper","year":"2019","journal-title":"CNS Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/NEN.0b013e3181919a48","article-title":"Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship","volume":"68","author":"Nelson","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer\u2019s disease","volume":"6","author":"Yiannopoulou","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","article-title":"New approaches to symptomatic treatments for Alzheimer\u2019s disease","volume":"16","author":"Cummings","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"ref_28","first-page":"116","article-title":"Non-Pharmacologic Interventions for Persons with Dementia","volume":"114","author":"Stewart","year":"2017","journal-title":"Mo. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yu, T.W., Lane, H.Y., and Lin, C.H. (2021). Novel Therapeutic Approaches for Alzheimer\u2019s Disease: An Updated Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158208"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","article-title":"Alzheimer\u2019s disease: From immunotherapy to immunoprevention","volume":"186","author":"Jucker","year":"2023","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment Combinations for Alzheimer\u2019s Disease: Current and Future Pharmacotherapy Options","volume":"67","author":"Cummings","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-144-2-200601170-00004","article-title":"Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older","volume":"144","author":"Larson","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","article-title":"A review on Alzheimer\u2019s disease pathophysiology and its management: An update","volume":"67","author":"Kumar","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"ref_34","first-page":"CD003154","article-title":"Memantine for dementia","volume":"2","author":"McShane","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_35","unstructured":"Kuns, B., Rosani, A., Patel, P., and Varghese, D. (2024). StatPearls, StatPearls Publishing LLC."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ryu, W.-S. (2017). Molecular Virology of Human Pathogenic Viruses, Academic Press.","DOI":"10.1016\/B978-0-12-800838-6.00010-2"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archneur.63.1.49","article-title":"A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease","volume":"63","author":"Reisberg","year":"2006","journal-title":"Arch. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of Aducanumab for Alzheimer Disease\u2014The FDA\u2019s Perspective","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Tampi, R.R., Forester, B.P., and Agronin, M. (2021). Aducanumab: Evidence from clinical trial data and controversies. Drugs Context, 10.","DOI":"10.7573\/dic.2021-7-3"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4103\/1673-5374.320970","article-title":"Pathological mechanisms and therapeutic strategies for Alzheimer\u2019s disease","volume":"17","author":"Ju","year":"2022","journal-title":"Neural. Regen. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e066289","DOI":"10.1002\/alz.066289","article-title":"Lecanemab (BAN2401) Infusion Reactions and Immunogenicity: Results from Randomized Phase 2 Study and an Open-Label Extension (OLE)","volume":"18","author":"Landry","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_43","first-page":"9343514","article-title":"Aducanumab Therapy to Treat Alzheimer\u2019s Disease: A Narrative Review","volume":"2022","author":"Beshir","year":"2022","journal-title":"Int. J. Alzheimers Dis."},{"key":"ref_44","first-page":"221","article-title":"Aducanumab: Appropriate Use Recommendations Update","volume":"9","author":"Cummings","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/nop2.878","article-title":"Aducanumab for Alzheimer\u2019s disease: The never-ending story that nurses should know","volume":"8","author":"Petch","year":"2021","journal-title":"Nurs. Open"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"870517","DOI":"10.3389\/fnagi.2022.870517","article-title":"Impact of Anti-amyloid-\u03b2 Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer\u2019s Disease: A Focus on Aducanumab and Lecanemab","volume":"14","author":"Shi","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e12295","DOI":"10.1002\/trc2.12295","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12967-024-05248-x","article-title":"Passive immunotherapy for Alzheimer's disease: Challenges & future directions","volume":"22","author":"Yi","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e12112","DOI":"10.1002\/trc2.12112","article-title":"Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease","volume":"7","author":"Lowe","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Lu, R.-M., Hwang, Y.-C., Liu, I.J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., and Wu, H.-C. (2020). Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci., 27.","DOI":"10.1186\/s12929-019-0592-z"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e230009","DOI":"10.1148\/rg.230009","article-title":"Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti\u2013Amyloid-\u03b2 Therapy","volume":"43","author":"Agarwal","year":"2023","journal-title":"RadioGraphics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1126\/science.1152993","article-title":"Differential regulation of dynein and kinesin motor proteins by tau","volume":"319","author":"Dixit","year":"2008","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2016.5755","article-title":"Association of in vivo [18F] AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease","volume":"74","author":"Xia","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/WNR.0b013e32818b2a0b","article-title":"14-3-3 proteins and protein phosphatases are not reduced in tau-deficient mice","volume":"18","author":"Fujio","year":"2007","journal-title":"Neuroreport"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.neurobiolaging.2012.12.003","article-title":"Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice","volume":"34","author":"Morris","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: A phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med."},{"key":"ref_62","unstructured":"Biogen (2023, October 25). New Data from Biogen\u2019s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer\u2019s Disease. Available online: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/new-data-biogens-investigational-antisense-oligonucleotide-aso."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"43223","DOI":"10.1074\/jbc.M112.396176","article-title":"Tau oligomers impair artificial membrane integrity and cellular viability","volume":"287","author":"Flach","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e076888","DOI":"10.1002\/alz.076888","article-title":"APNmAb005, an anti-tau antibody targeting synaptic tau oligomers, in Phase 1 for treatment of Alzheimer\u2019s Disease and primary tauopathies","volume":"19","author":"Tai","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e12097","DOI":"10.1002\/trc2.12097","article-title":"Novel antibody against low-n oligomers of tau protein promotes clearance of tau in cells via lysosomes","volume":"6","author":"Chandupatla","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref_66","unstructured":"ClinicalTrials.gov (2024, April 30). A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants with Early Alzheimer\u2019s Disease (INVOKE-2). ClinicalTrials.gov, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04592874."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer\u2019s disease\u2014Results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.57.3.481","article-title":"A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients","volume":"57","author":"Mohs","year":"2001","journal-title":"Neurology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: International randomised controlled trial","volume":"318","author":"Anand","year":"1999","journal-title":"BMJ"},{"key":"ref_70","first-page":"Cd001191","article-title":"Rivastigmine for Alzheimer\u2019s disease","volume":"2","author":"Birks","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer\u2019s disease: A randomised, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"ref_73","unstructured":"Martin, C.R., and Preedy, V.R. (2020). Diagnosis and Management in Dementia, Academic Press."},{"key":"ref_74","first-page":"Cd013306","article-title":"Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: A network meta-analysis","volume":"2","author":"Battle","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/psyg.12944","article-title":"Aducanumab for the treatment of Alzheimer\u2019s disease: A systematic review","volume":"23","author":"Rahman","year":"2023","journal-title":"Psychogeriatrics"},{"key":"ref_76","first-page":"197","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","author":"Aisen","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1370\/afm.3050","article-title":"Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis","volume":"22","author":"Ebell","year":"2024","journal-title":"Ann. Fam. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbr.2009.01.013","article-title":"Impaired hippocampus-dependent and-independent learning in IL-6 deficient mice","volume":"200","author":"Baier","year":"2009","journal-title":"Behav. Brain Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1742-2094-5-38","article-title":"Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism","volume":"5","author":"Semmler","year":"2008","journal-title":"J. Neuroinflamm."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Bartsch, T. (2012). The Clinical Neurobiology of the Hippocampus: An Integrative View, Oxford University Press.","DOI":"10.1093\/acprof:oso\/9780199592388.001.0001"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s12272-010-1006-7","article-title":"Inflammation and Alzheimer\u2019s disease","volume":"33","author":"Lee","year":"2010","journal-title":"Arch. Pharmacal Res."},{"key":"ref_82","first-page":"a006346","article-title":"Inflammation in Alzheimer disease\u2014A brief review of the basic science and clinical literature","volume":"2","author":"Rogers","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e140122192307","DOI":"10.2174\/1570163818666210316114331","article-title":"Drug Repositioning: A Unique Approach to Refurbish Drug Discovery","volume":"19","author":"Kale","year":"2022","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/2589977513666210211163711","article-title":"Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery","volume":"13","author":"Roy","year":"2021","journal-title":"Curr. Drug Res. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Krishnamurthy, N., Grimshaw, A.A., Axson, S.A., Choe, S.H., and Miller, J.E. (2022). Drug repurposing: A systematic review on root causes, barriers and facilitators. BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-08272-z"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Sahoo, B.M., Ravi Kumar, B.V.V., Sruti, J., Mahapatra, M.K., Banik, B.K., and Borah, P. (2021). Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.628144"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Iqbal, U.H., Zeng, E., and Pasinetti, G.M. (2020). The Use of Antimicrobial and Antiviral Drugs in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144920"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00213-020-05503-1","article-title":"The combination of acyclovir and dexamethasone protects against Alzheimer\u2019s disease-related cognitive impairments in mice","volume":"237","author":"Hui","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Wozniak, M.A., Frost, A.L., Preston, C.M., and Itzhaki, R.F. (2011). Antivirals reduce the formation of key Alzheimer\u2019s disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025152"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.trci.2016.05.001","article-title":"The roles of inflammation and immune mechanisms in Alzheimer\u2019s disease","volume":"2","author":"Carrillo","year":"2016","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"fcaa109","DOI":"10.1093\/braincomms\/fcaa109","article-title":"Anti-inflammatories in Alzheimer\u2019s disease\u2014Potential therapy or spurious correlate?","volume":"2","author":"Mather","year":"2020","journal-title":"Brain Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1533317514542644","article-title":"Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer\u2019s disease: A meta-analysis of randomized clinical trials","volume":"30","author":"Gupta","year":"2015","journal-title":"Am. J. Alzheimer\u2019s Dis. Other Dement."},{"key":"ref_93","first-page":"e4620","article-title":"Recommendations for Anti-inflammatory Treatments in Alzheimer\u2019s Disease: A Comprehensive Review of the Literature","volume":"11","author":"Ali","year":"2019","journal-title":"Cureus"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"907804","DOI":"10.3389\/fimmu.2022.907804","article-title":"Neuroinflammation in neurodegeneration via microbial infections","volume":"13","author":"Tran","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jnc.13607","article-title":"Neuroinflammation: The devil is in the details","volume":"139","author":"DiSabato","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jocn.2009.05.006","article-title":"The role of microglia in central nervous system immunity and glioma immunology","volume":"17","author":"Yang","year":"2010","journal-title":"J. Clin. Neurosci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia Function in the Central Nervous System During Health and Neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3389\/fncel.2018.00488","article-title":"Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response","volume":"12","author":"Bachiller","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"ref_99","first-page":"24","article-title":"Glial Cells and Their Function in the Adult Brain: A Journey through the History of Their Ablation","volume":"11","author":"Dimou","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00401-009-0619-8","article-title":"Astrocytes: Biology and pathology","volume":"119","author":"Sofroniew","year":"2010","journal-title":"Acta Neuropathol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/pr.115.011833","article-title":"Endothelin","volume":"68","author":"Davenport","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"108182","DOI":"10.1016\/j.neuropharm.2020.108182","article-title":"Endothelin receptor antagonists alleviate blood-brain barrier disruption and cerebral edema in a mouse model of traumatic brain injury: A comparison between bosentan and ambrisentan","volume":"175","author":"Michinaga","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/glia.23981","article-title":"Reactive astrocytes as treatment targets in Alzheimer\u2019s disease\u2014Systematic review of studies using the APPswePS1dE9 mouse model","volume":"69","author":"Smit","year":"2021","journal-title":"Glia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"664","DOI":"10.14336\/AD.2018.0720","article-title":"Reactive Astrocytes in Neurodegenerative Diseases","volume":"10","author":"Li","year":"2019","journal-title":"Aging Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.immuni.2017.06.006","article-title":"Reactive Astrocytes: Production, Function, and Therapeutic Potential","volume":"46","author":"Liddelow","year":"2017","journal-title":"Immunity"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3233\/JAD-2012-111760","article-title":"Endothelin-1 is elevated in Alzheimer\u2019s disease and upregulated by amyloid-\u03b2","volume":"29","author":"Palmer","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1089\/neu.2017.5421","article-title":"Delayed Administration of BQ788, an ET(B) Antagonist, after Experimental Traumatic Brain Injury Promotes Recovery of Blood-Brain Barrier Function and a Reduction of Cerebral Edema in Mice","volume":"35","author":"Michinaga","year":"2018","journal-title":"J. Neurotrauma"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1471-4159.2011.07610.x","article-title":"STAT3 signaling after traumatic brain injury","volume":"120","author":"Oliva","year":"2012","journal-title":"J. Neurochem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12964-020-00549-2","article-title":"Dual roles of astrocytes in plasticity and reconstruction after traumatic brain injury","volume":"18","author":"Zhou","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"792764","DOI":"10.3389\/fncel.2021.792764","article-title":"Reactive Astrocytes in Central Nervous System Injury: Subgroup and Potential Therapy","volume":"15","author":"Yu","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Koyama, Y. (2021). Endothelin ET(B) Receptor-Mediated Astrocytic Activation: Pathological Roles in Brain Disorders. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094333"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1017\/S0033291700033420","article-title":"Neuropsychiatric and neuropsychological correlates of delusions in Alzheimer\u2019s disease","volume":"25","author":"Migliorelli","year":"1995","journal-title":"Psychol. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.neubiorev.2021.05.005","article-title":"Anxiety and Alzheimer\u2019s disease: Behavioral analysis and neural basis in rodent models of Alzheimer\u2019s-related neuropathology","volume":"127","author":"Pentkowski","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"M348","DOI":"10.1093\/gerona\/54.7.M348","article-title":"Anxiety in Alzheimer\u2019s Disease: Prevalence and Comorbidity","volume":"54","author":"Teri","year":"1999","journal-title":"J. Gerontol. Ser. A Biol. Sci. Med. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","article-title":"Medication Augmentation after the Failure of SSRIs for Depression","volume":"354","author":"Trivedi","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_116","first-page":"4","article-title":"History and evolution of the monoamine hypothesis of depression","volume":"61","author":"Hirschfeld","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41586-018-0255-3","article-title":"Structure of a human synaptic GABAA receptor","volume":"559","author":"Zhu","year":"2018","journal-title":"Nature"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1074\/jbc.M113.514695","article-title":"GABAA receptor \u03b1 and \u03b3 subunits shape synaptic currents via different mechanisms","volume":"289","author":"Dixon","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"616298","DOI":"10.3389\/fnins.2020.616298","article-title":"Looking for Novelty in an \u201cOld\u201d Receptor: Recent Advances Toward Our Understanding of GABAARs and Their Implications in Receptor Pharmacology","volume":"14","author":"Castellano","year":"2021","journal-title":"Front. Neurosci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pharmthera.2012.08.006","article-title":"\u03b12-containing GABA(A) receptors: A target for the development of novel treatment strategies for CNS disorders","volume":"136","author":"Engin","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0022-510X(77)90073-9","article-title":"Neurotransmitter enzyme abnormalities in senile dementia: Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue","volume":"34","author":"Perry","year":"1977","journal-title":"J. Neurol. Sci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/brain\/105.2.313","article-title":"A post-mortem study of the cholinergic and GABA systems in senile dementia","volume":"105","author":"Rossor","year":"1982","journal-title":"Brain J. Neurol."},{"key":"ref_123","unstructured":"Millar, A. (2021, December 13). The Drugs Fighting Memory Loss. Available online: https:\/\/www.pharmaceutical-technology.com\/features\/memory-loss-drugs-reverse\/."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"822499","DOI":"10.3389\/fphar.2022.822499","article-title":"Alzheimer\u2019s Disease Enhanced Tonic Inhibition is Correlated With Upregulated Astrocyte GABA Transporter-3\/4 in a Knock-In APP Mouse Model","volume":"13","author":"Aldabbagh","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/cercor\/bhz016","article-title":"Aberrant Excitatory-Inhibitory Synaptic Mechanisms in Entorhinal Cortex Microcircuits During the Pathogenesis of Alzheimer\u2019s Disease","volume":"29","author":"Petrache","year":"2019","journal-title":"Cereb. Cortex"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"568194","DOI":"10.3389\/fncel.2020.568194","article-title":"Selective Modulation of alpha5 GABA(A) Receptors Exacerbates Aberrant Inhibition at Key Hippocampal Neuronal Circuits in APP Mouse Model of Alzheimer\u2019s Disease","volume":"14","author":"Petrache","year":"2020","journal-title":"Front. Cell Neurosci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/cercor\/bhz165","article-title":"Preserved Calretinin Interneurons in an App Model of Alzheimer\u2019s Disease Disrupt Hippocampal Inhibition via Upregulated P2Y1 Purinoreceptors","volume":"30","author":"Shi","year":"2019","journal-title":"Cereb. Cortex"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e13129","DOI":"10.1111\/bpa.13129","article-title":"The fate of interneurons, GABA(A) receptor sub-types and perineuronal nets in Alzheimer\u2019s disease","volume":"33","author":"Ali","year":"2023","journal-title":"Brain Pathol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1523\/JNEUROSCI.3340-09.2009","article-title":"Extrasynaptic GABAA receptors: Form, pharmacology, and function","volume":"29","author":"Belelli","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","article-title":"Extrasynaptic GABA(A) receptors: Their function in the CNS and implications for disease","volume":"73","author":"Brickley","year":"2012","journal-title":"Neuron"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1152\/jn.2002.87.5.2624","article-title":"Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells","volume":"87","author":"Nusser","year":"2002","journal-title":"J. Neurophysiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"108333","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00213-016-4243-8","article-title":"Comparing the discriminative stimulus effects of modulators of GABAA receptors containing \u03b14-\u03b4 subunits with those of gaboxadol in rats","volume":"233","author":"Zanettini","year":"2016","journal-title":"Psychopharmacology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuropharm.2014.08.003","article-title":"Altered expression of \u03b4GABAA receptors in health and disease","volume":"88","author":"Whissell","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/BF00432116","article-title":"Effects of THIP on chronic anxiety","volume":"80","year":"1983","journal-title":"Psychopharmacology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fnbeh.2019.00141","article-title":"Gaboxadol Normalizes Behavioral Abnormalities in a Mouse Model of Fragile X Syndrome","volume":"13","author":"Cogram","year":"2019","journal-title":"Front. Behav. Neurosci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/10\/5169\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:42:50Z","timestamp":1760107370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/10\/5169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":136,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25105169"],"URL":"https:\/\/doi.org\/10.3390\/ijms25105169","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}